Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biotricity, Inc. stock logo
BTCY
Biotricity
$0.12
+4.6%		$0.12
$0.09
▼
$0.75
$2.43M1.1353,003 shs8,485 shs
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.01
$0.04
▼
$0.19
$653K0.311,976 shs20 shs
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
$0.29
-10.9%		$0.39
$0.25
▼
$14.14
$2.22M0.76.23 million shs1.30 million shs
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
$2.86
+3.3%		$3.33
$2.50
▼
$21.75
$2.29M1.351.16 million shs19,234 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biotricity, Inc. stock logo
BTCY
Biotricity
+4.62%-0.66%+5.02%-8.40%-78.91%
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00%0.00%0.00%0.00%-89.00%
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
-5.61%-7.94%+5.66%-50.60%-92.52%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
-4.81%-12.89%-10.65%-47.64%-82.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biotricity, Inc. stock logo
BTCY
Biotricity
$0.12
+4.6%		$0.12
$0.09
▼
$0.75
$2.43M1.1353,003 shs8,485 shs
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.01
$0.04
▼
$0.19
$653K0.311,976 shs20 shs
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
$0.29
-10.9%		$0.39
$0.25
▼
$14.14
$2.22M0.76.23 million shs1.30 million shs
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
$2.86
+3.3%		$3.33
$2.50
▼
$21.75
$2.29M1.351.16 million shs19,234 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biotricity, Inc. stock logo
BTCY
Biotricity
+4.62%-0.66%+5.02%-8.40%-78.91%
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00%0.00%0.00%0.00%-89.00%
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
-5.61%-7.94%+5.66%-50.60%-92.52%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
-4.81%-12.89%-10.65%-47.64%-82.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biotricity, Inc. stock logo
BTCY
Biotricity
0.00
N/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00
N/AN/AN/A
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
1.00
SellN/AN/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
2.00
Hold$25.00773.82% Upside

Current Analyst Ratings Breakdown

Latest DYNT, GCTK, BTCY, and VRAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/6/2026
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biotricity, Inc. stock logo
BTCY
Biotricity
$12.06M0.20N/AN/A($1.30) per share-0.09
Dynatronics Co. stock logo
DYNT
Dynatronics
$33.60M0.00N/AN/A$0.57 per share0.00
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/AN/AN/AN/A($0.23) per shareN/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
$10K228.88N/AN/A$42.23 per share0.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biotricity, Inc. stock logo
BTCY
Biotricity
-$14.09M-$0.14N/AN/AN/A-80.42%N/A-188.47%11/12/2026 (Estimated)
Dynatronics Co. stock logo
DYNT
Dynatronics
-$2.70M-$1.35N/AN/AN/A-8.35%-41.81%-9.56%N/A
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
-$19.39M-$9.18N/AN/AN/AN/A-2,135.52%-290.22%N/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
-$5.02MN/AN/AN/AN/AN/AN/AN/AN/A

Latest DYNT, GCTK, BTCY, and VRAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/A$0.76N/A$0.76N/AN/A
7/3/2026Q4 2026
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
-$1.75-$0.1950+$1.5550-$0.1950$0.00 million$0.01 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biotricity, Inc. stock logo
BTCY
Biotricity
N/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/A
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/AN/AN/AN/AN/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biotricity, Inc. stock logo
BTCY
Biotricity
N/A
0.23
0.10
Dynatronics Co. stock logo
DYNT
Dynatronics
0.25
1.21
0.60
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
0.08
0.46
0.46
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
N/A
9.97
9.97

Institutional Ownership

CompanyInstitutional Ownership
Biotricity, Inc. stock logo
BTCY
Biotricity
3.89%
Dynatronics Co. stock logo
DYNT
Dynatronics
4.18%
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
10.92%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
8.61%

Insider Ownership

CompanyInsider Ownership
Biotricity, Inc. stock logo
BTCY
Biotricity
1.60%
Dynatronics Co. stock logo
DYNT
Dynatronics
2.90%
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
5.90%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
45.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biotricity, Inc. stock logo
BTCY
Biotricity
4020.24 million22.08 millionNo Data
Dynatronics Co. stock logo
DYNT
Dynatronics
20016.05 million8.11 millionNot Optionable
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
57.72 million7.26 millionNot Optionable
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
5800,000438,000Not Optionable

Recent News About These Companies

Virax Biolabs Shareholders Approve Major Capital Increase but Reject Governance Overhaul
August 26 at 5:11 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/virax-biolabs-shareholders-approve-major-capital-increase-but-reject-governance-overhaul?utm_source=marketbeat.com&utm_medium=referral
Join Virax’s Live Investor Webinar: Advancing Immune Diagnostics, Clinical Development and Commercial Execution
August 20, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/40717/join-viraxs-live-investor-webinar-advancing-immune-diagnostics-clinical-development-and-commercial-execution/
Virax Biolabs Calls August 14 EGM to Approve Major Share Capital Increase
August 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VRAX/pressreleases/3593481/virax-biolabs-calls-august-14-egm-to-approve-major-share-capital-increase/
RedChip Companies, Inc.: Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money Show on Bloomberg TV
July 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69071897-redchip-companies-inc-alliance-entertainment-and-virax-interviews-aired-on-the-redchip-small-stocks-big-money-show-on-bloomberg-tv-200.htm
Virax Biolabs Boosts Liquidity, Secures Fosun Deal and Restores Nasdaq Compliance After Fiscal 2026 Report
July 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/virax-biolabs-boosts-liquidity-secures-fosun-deal-and-restores-nasdaq-compliance-after-fiscal-2026-report?utm_source=marketbeat.com&utm_medium=referral
Virax BioLabs Group Limited: Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
July 16, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69047250-virax-biolabs-group-limited-virax-biolabs-ceo-james-foster-provides-shareholder-update-following-fiscal-2026-annual-report-and-fosun-diagnostics-com-008.htm
Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
July 16, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/virax-biolabs-ceo-james-foster-provides-shareholder-update-following-fiscal-2026-annual-report-and-fosun-diagnostics-commercial-supply-agreement-302827504.html
Virax Biolabs Raises $3.3 Million via Exercise of Investment Options and Issues New Warrants
July 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/virax-biolabs-raises-3-3-million-via-exercise-of-investment-options-and-issues-new-warrants?utm_source=marketbeat.com&utm_medium=referral
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
July 10, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/virax-biolabs-group-limited-announces-closing-of-exercise-of-preferred-investment-options-for-3-3-million-gross-proceeds-302823045.html
Virax Biolabs Group Limited Ordinary Shares (VRAX) Institutional Holdings
July 10, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/vrax/institutional-holdings
Virax Biolabs stock skyrockets 100% on exclusive distribution agreement
July 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/virax-biolabs-stock-skyrockets-100-on-exclusive-distribution-agreement/ar-AA27AHhS
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
July 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/virax-biolabs-group-limited-announces-exercise-of-preferred-investment-options-for-3-3-million-gross-proceeds-302822153.html
Virax Biolabs shares double after exclusive Fosun distribution agreement (VRAX)
July 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/virax-biolabs-shares-double-after-exclusive-fosun-distribution-agreement-vrax/ar-AA27zFgp
Why this biotech stock more than tripled on Thursday
July 9, 2026  |  invezz.comI
Virax Biolabs Jumps on Fosun Diagnostics Supply Agreement
July 9, 2026  |  quiverquant.comQ
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
July 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/virax-biolabs-signs-multi-country-commercial-supply-agreement-with-fosun-diagnostics-302820805.html
Virax Biolabs Group announces 1-for-25 share consolidation
June 25, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/virax-biolabs-group-announces-1-for-25-share-consolidation/ar-AA26qRAN
Virax Biolabs Approves 1-for-25 Share Consolidation to Maintain Nasdaq Listing
June 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/virax-biolabs-approves-1-for-25-share-consolidation-to-maintain-nasdaq-listing?utm_source=marketbeat.com&utm_medium=referral
Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation
June 24, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/virax-biolabs-group-limited-announces-1-for-25-share-consolidation-302808727.html
Virax BioLabs Group Limited: Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune in Long COVID and Related Post-Acute Infection Syndromes
May 26, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68594646-virax-biolabs-group-limited-virax-biolabs-reports-positive-early-clinical-data-for-viraximmune-in-long-covid-and-related-post-acute-infection-syndrom-008.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biotricity stock logo

Biotricity NASDAQ:BTCY

$0.12 +0.01 (+4.62%)
As of 11:42 AM Eastern

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

Dynatronics stock logo

Dynatronics NASDAQ:DYNT

Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.

GlucoTrack stock logo

GlucoTrack NASDAQ:GCTK

$0.29 -0.04 (-10.93%)
As of 12:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

Virax Biolabs Group stock logo

Virax Biolabs Group NASDAQ:VRAX

$2.86 +0.09 (+3.29%)
As of 12:36 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas